An observational study in HIV-1-infection and Hiv, sponsored by Helios Salud. Status unknown at 1 site in Argentina. Open to female participants. Per ClinicalTrials.gov, last updated 2020-10-28.
Sponsored by Helios Salud · Observational
A cross-sectional study that uses ecological data from (1) PLWHIV under care at 31st December 2017, and (2) from yearly admissions to care occurred during 2013 - 2017, from centers belonging to LAW-HIV.
General Aims Aim 1: Epidemiological and clinical description of women that receive HIV care in selected countries of Latin America.
Aim 2: Management of HIV infection during pregnancy in women from selected countries of Latin America.
Countries: Argentina, Bolivia, Chile, Colombia, Costa Rica,Ecuador, Guatemala, Honduras, México, Peru, Dominican, Republic, Uruguay, and Venezuela.
Background \& Relevance of this specific study:
Research Approach:
The Latin American Workshop for HIV Studies (LAW-HIV) includes more than 70 clinical centers belonging to 14 Spanish speaking countries from the region. It gathers aggregate information form more than 116.000 people living with HIV under care, from which 25,802 are women.
These numbers represent roughly a fifth of the total estimated female under care in these countries.
Specific aims from overall aim 1:
The investigators will determine at center, national and regional level:
Specific aims from overall aim 2:
The investigators will determine:
Study Design:
A cross-sectional study that uses ecological data from (1) People living with HIV under care at 31st December 2017, and (2) from yearly admissions to care occurred during 2013 - 2017, from centers belonging to LAW-HIV. Data will be weighted by the expected population under care in each country considering attributes of the centers (private/public). Weighted outcomes at strata level from each center will be meta-analyzed considering three levels of heterogeneity (stratum, center, and country) and modeled through multilevel regression models to allow adjustment for covariables of the stratum. In the case of admissions to care, a time series analysis will be implemented.
Data collection and quality control:
Data collection will be carried out through a spreadsheet sent to centers that agree to participate. Two different spreadsheets will be sent, one for each general aim of the study (see the annex at the complete project). A quality check will be implemented at three stages: (1) at the moment of receiving each spreadsheet back; (2) previous to analysis, where the consistency of information across strata from different sections will be assessed; and (3) identifying outlier values from outcomes at the centers level, using expert criteria.
Data information included:
Total duration: 18 months.
Helios Salud is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
For the overall aim 1, the investigators expected to include information about 25,816 women under care, and between 6,000 and 7,500 women admitted during 2013 - 2017 (depending on the sub-analysis), from 14 countries and 79 centers.
For the overall aim 2, the investigators expect to include aggregated information from roughly 400 pregnant females, from at least ten countries. It is worth noticing that the analytic unit corresponds to the information at the stratum level and depending on the disposition of the information in the database, the total numbers of strata will vary between approximately 400 to 8.000.
Epidemiological and clinical description of women that receive HIV care in selected countries of Latin America.
1.1. In women admitted to care between years 2013-2017, the trend in the: * distribution of ages; * proportion of late presenters (CD4). * proportion that start ART during the first year after admission; * schemes of ART used for the first ART. 1.2. Proportion of women alive, retained to care, retained to ART, and with virologic suppression at one year of follow up, from admissions occurred in 2016.
Time frame: 1 year
Management of HIV infection during pregnancy in women from selected countries of Latin America.
2. In women that finished their pregnancy at any moment during 2019: * Proportion with HIV diagnosis as consequence of the pregnancy. * Earliest CD4 level. * Proportion that suspended ART during pregnancy * Frequency of each scheme of ART used previous the conception * Change of scheme of ART * Proportion whose pregnancy ended in term * Proportion retained in care during the first 6 months after pregnancy * Proportion that suspended breastfeeding during the first 3 months after pregnancy
Time frame: 1 year
This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Helios Salud